88 results
424B5
ADCT
Adc Therapeutics SA
6 May 24
Prospectus supplement for primary offering
6:51am
and increase against payment of contributions in cash, a resolution passed by a majority of the shares represented at the general meeting … into share capital is involved, a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the majority of the par
10-Q
2024 Q1
ADCT
Adc Therapeutics SA
6 May 24
Quarterly report
6:38am
, evidence of anti-tumor activity (complete response or partial response) was observed among the majority of patients, with mixed histologies including … DLBCL, follicular lymphoma (“FL”) and marginal zone lymphoma (“MZL”). In addition, as of April 19, 2024, initial safety findings showed that the majority
8-K
EX-99.1
ADCT
Adc Therapeutics SA
6 May 24
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
6:29am
of anti-tumor activity (complete response or partial response) was observed among the majority of patients, with mixed histologies including r/r DLBCL … , follicular lymphoma (FL) and marginal zone lymphoma (MZL). In addition, as of April 19, 2024, initial safety findings showed that the majority of CRS
8-K
EX-99.2
ADCT
Adc Therapeutics SA
6 May 24
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
6:29am
, evidence of anti- tumor activity (complete response or partial response) was observed among the majority of patients Majority of CRS events were grade
DEF 14A
ADCT
Adc Therapeutics SA
26 Apr 24
Definitive proxy
4:05pm
required to approve the proposals and how are votes counted?
The affirmative vote of a majority of votes represented at the Annual Meeting … on the result of these proposals.
The affirmative vote of a majority of votes cast is required for Proposal #11 (approving, on an advisory basis under U.S
PRE 14A
xx69vvh1av8
16 Apr 24
Preliminary proxy
4:16pm
8-K
EX-99.1
di19qt
9 Apr 24
3 Agenda ▪ Business Update ▪ Our Research Strategy ▪ Our Platform ▪ Lead Candidates ▪ Forward Looking ▪ Closing Remarks ▪ Q&A
4:06pm
424B3
04myibq98l3271
15 Mar 24
Prospectus supplement
4:11pm
424B3
k5n4n y5q8i9ue
15 Mar 24
Prospectus supplement
4:11pm
POS AM
3o7v4 jxoq1lsi0
13 Mar 24
Prospectus update (post-effective amendment)
4:17pm
POS AM
53kqouc
13 Mar 24
Prospectus update (post-effective amendment)
4:16pm
POS AM
ivw5px khp4k7v3qvy
13 Mar 24
Prospectus update (post-effective amendment)
4:14pm
10-K
EX-97.1
ia9j9y5h2wsqeg
13 Mar 24
Annual report
12:25pm
10-K
v963p41 7u6fez2d70hx
13 Mar 24
Annual report
12:25pm
10-K
EX-4.1
hgi 0lnhdskj3rlar1s
13 Mar 24
Annual report
12:25pm
8-K
EX-99.2
hv7t7wtq
13 Mar 24
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
7:39am
8-K
EX-99.1
kljk1f6vg87bigcf8
13 Mar 24
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
7:39am
8-K
EX-99.2
6n9djm t9u
4 Jan 24
ADC Therapeutics Provides Business Updates
7:00am
8-K
EX-99.1
6em1b09zek3wdf xtcmo
4 Jan 24
ADC Therapeutics Provides Business Updates
7:00am
S-8
EX-99.1
3eyfv 2ts123xo8q8vo
4 Dec 23
Registration of securities for employees
4:57pm